>latest-news

Aligos Therapeutics Appoints Laura Kavanaugh As VP, Head Of Legal To Support Clinical And Corporate Growth

Aligos Therapeutics appoints Laura Kavanaugh as VP, Head of Legal, bringing 25+ years of legal leadership in biotech and pharma.

Breaking News

  • May 21, 2025

  • Simantini Singh Deo

Aligos Therapeutics Appoints Laura Kavanaugh As VP, Head Of Legal To Support Clinical And Corporate Growth

Aligos Therapeutics, Inc. has announced the appointment of Laura Kavanaugh, JD, as Vice President, Head of Legal, effective immediately. Kavanaugh brings over 25 years of legal and leadership experience in the biotech and pharmaceutical sectors, where she has advised on corporate law, compliance, privacy, and development strategy. 

“I am thrilled to welcome Laura to the Aligos team. Laura brings with her a wealth of experience in all legal aspects from both biotech companies as well as large pharmaceutical firms. Her extensive knowledge and broad expertise will undoubtedly provide invaluable leadership and oversight on all legal matters,” said Lesley Ann Calhoun, Executive Vice President, Chief Operating Officer, and Chief Financial Officer at Aligos.

Before joining Aligos, Kavanaugh most recently served as VP of Corporate Law and Privacy Officer at Codexis. She has also consulted for notable biotech companies, including Genentech, Elan Pharmaceuticals, Allakos, ZS Pharma, and Principia, and previously held key in-house legal roles, including Practice Group Leader of BioOncology Development Law at Genentech. Her career began at a well-regarded law firm in Silicon Valley.

“I am honored to join the dynamic team at Aligos. I look forward to working with my new colleagues to navigate the complex legal landscape to drive forward our mission of improving patient outcomes,” stated Laura Kavanaugh, Vice President, Head of Legal at Aligos.

Kavanaugh earned his BA at the University of California, Berkeley and his JD from Santa Clara University Law School. Aligos expects her experience in these fields will boost its growth, especially as it progresses through clinical testing of therapies for liver and viral disorders.

Ad
Advertisement